| | | 20,000+ Fresh Resumes Monthly | |
|
|
| |
Click here or scroll down to respond to this candidateCandidate's Name , MSAnalytics Consultant IIITMF Health Quality InstituteSummary of Key Knowledge and SkillsDeveloping and generating reports and analyses datasetsResearch designMeasures developmentData analysisData collectionData managementSAS experienceTMF EXPERIENCEAnalytic Consultant (2018 Present)Provide analytic support for First-look Analysis Tool for Hospital Outlier Monitoring (FATHOM) and Program for Evaluating Payment Patterns Electronic Report (PEPPER) reports distributed to the Centers for Medicare & Medicaid Services (CMS), Fiscal Intermediaries (FIs), Medicare Administrative Contractors (MACs) and short-term acute care hospitals, critical access hospitals, home health agencies, hospices, inpatient psychiatric facilities, inpatient rehabilitation facilities, long-term acute care hospitals, partial hospitalization programs and skilled nursing facilities.Define data requirements and analyze program data using statistical and relational databasesoftware.Design, produce, analyze and debug routine data reports.Report results of statistical analyses (i.e., graphs, charts, tables, written reports).Research contents, limitations, and potential uses of all available data sets relevant to assigned task areas.Develop documentation for all analyses to include storage location of all files (i.e., program code, data sets, output); thoroughly document program code and monitors use of disk storage, archiving data sets when not in use.Develop measures to assess contract performance in assigned task areas, and make changes to those measures as required with contract modifications.Collaborate with others in the organization to ensure successful implementation of chosen problem solutions.Collaborate with other members of the Analytic group by checking program code for adherence to specifications and checking output for correct results.Provide technical support to customers including answering questions, trouble-shooting problems and assisting in modification of program code.PRIOR EXPERIENCETexas Health and Human Services Commission,Austin, TXSupervisor (2015 2018)Developed and implemented all rehab policies and procedures.Obtained approval by the Fiscal Intermediary for the Clinical Documentation System.Developed and implemented training and strategies to address the new Inpatient Rehab Hospital Prospective Payment System.Cenpatico, Austin, TXQuality Improvement Analyst (2014 2015)Developed and implemented multiple interdisciplinary therapeutic day programs.Oversaw long-range planning for the entire facility.ACS/Texas Medicaid and Healthcare Partnership (TMHP), Austin, TXBusiness Analyst (2013 2014)Developed and implemented multiple interdisciplinary therapeutic day programs.Oversaw long-range planning for the entire facility.Kaiser Permanente Medical Group, Denver, COData Analyst (2013)Developed and implemented multiple interdisciplinary therapeutic day programs.Oversaw long-range planning for the entire facility.Colorado Foundation for Medical Care, Englewood, COBiostatistician (2009 2013)Developed and implemented multiple interdisciplinary therapeutic day programs.Oversaw long-range planning for the entire facility.PUBLICATIONS1.Zhou J, Brinckerhoff C, Lubert S, Yang K, Saini J, Hooke J, Mural R, Shriver C, Somiari S. Analysisofmatrix metalloproteinase-1 gene polymorphisms andexpression in benign and malignant breast tumors. Cancer Invest. 2011 Nov;29(9):599-607.2.Yang K, Tang Y, Iczkowski KA. Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression.Am J Transl Res. 2010 Jan 1;2(1):88-94.3.Yang K, Tang Y, Habermehl GK, Iczkowski KA. Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.BMC Cancer. 2010 Jan 14;10:16.4.Handorean AM, Yang K, Robbins EW, Flaig TW, Iczkowski KA. Silibinin suppresses CD44 expression in prostate cancer cells. AM J Transl Res. 2009 Jan 1;1(1):80-6.5.Yang K, Handorean AM, and Iczkowski KA. MicroRNA 373 and 520c are downregulated in prostate cancer, suppress CD44 translation, and modulate prostate cancer cell invasion. Int J Clin Exp Pathol. 2009; 2 (4): 361-9.6.Yang K, Zhang L, Xu T, Heroux A, Zhao R. Crystal structure of the near C-terminal domain of Prp8 reveals analogy to ribosomal proteins. Proc Natl Acad Sci U S A., 2008 Sep 16; 105(37):13817-22.AWARDSThorkildsen Research Fellowship, 2007EDUCATIONDoctor of Biochemistry and Molecular GeneticsPeking Union Medical College, Peking, China, 2003Master of Science in Biostatistics University of Texas at Austin, School of Public Health, Aurora, CO, 2012Bachelor of Science in Preventive MedicineJilin University, 1995PROFESSIONAL MEMBERSHIPSMember, American Statistical Association, 2006 |
